Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated Recommendations for the Bioanalysis of Antibody-Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community.

The AAPS journal·2026
Same author

2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS (<u>PART 3A</u> - Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).

Bioanalysis·2026
Same author

Technical Considerations of Pharmacokinetic Assays for LNP-mRNA Drug Products by RT-qPCR.

The AAPS journal·2025
Same author

IQ Survey Results on Current Industry Practices-Part 1: Immunogenicity Risk Assessment.

Clinical pharmacology and therapeutics·2025
Same author

Correction to: Neutralizing Antibody Sample Testing and Report Harmonization.

The AAPS journal·2024
Same author

Neutralizing Antibody Sample Testing and Report Harmonization.

The AAPS journal·2024

Related Experiment Video

Updated: May 13, 2026

Eye Irritation Test (EIT) for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial (RhCE) Tissue Model
10:13

Eye Irritation Test (EIT) for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial (RhCE) Tissue Model

Published on: August 23, 2015

Alternative methods for ocular toxicology testing: validation, applications and troubleshooting.

Sanjay L Dholakiya1, Frank A Barile

  • 1St. John's University, College of Pharmacy and Health Sciences, Toxicology Division, Department of Pharmaceutical Sciences, Queens, NY 11439, USA.

Expert Opinion on Drug Metabolism & Toxicology
|March 27, 2013
PubMed
Summary
This summary is machine-generated.

Developing validated in vitro ocular toxicity tests remains a challenge. While several alternative methods exist, none fully replace the in vivo Draize rabbit eye test for all chemical irritancy ranges, hindering regulatory acceptance.

More Related Videos

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

Related Experiment Videos

Last Updated: May 13, 2026

Eye Irritation Test (EIT) for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial (RhCE) Tissue Model
10:13

Eye Irritation Test (EIT) for Hazard Identification of Eye Irritating Chemicals using Reconstructed Human Cornea-like Epithelial (RhCE) Tissue Model

Published on: August 23, 2015

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
14:20

High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury

Published on: June 16, 2018

Area of Science:

  • Ocular toxicology
  • In vitro testing
  • Regulatory science

Background:

  • Humanitarian concerns and scientific advancements drive the development of alternative in vitro ocular models.
  • Despite progress, no single in vitro test fully replaces the in vivo Draize rabbit eye test for all chemical classes and irritancy levels.
  • Validated alternative methods like BCOP, ICE, CM, and FL assays exist but face limited regulatory acceptance.

Purpose of the Study:

  • To review the background, protocols, applications, and validation status of tier-testing approaches for ocular toxicity.
  • To provide expert analysis and perspectives on current alternative ocular toxicity testing methods.
  • To discuss potential future developments in the field of in vitro ocular safety assessment.

Main Methods:

  • Review of existing literature on in vitro ocular toxicity testing methods.
  • Analysis of validation status and regulatory acceptance of various assays.
  • Expert opinion on the current state and future directions of alternative testing strategies.

Main Results:

  • Several in vitro ocular models have been developed and validated since the 1990s.
  • Limited regulatory acceptance for most validated in vitro ocular toxicity assays.
  • Refinements to in vivo testing, such as humane endpoints, have been accepted.

Conclusions:

  • Prioritization of techniques, mechanistic understanding, and statistical justification are crucial for developing replacement strategies for the Draize test.
  • Regulatory acceptance hinges on unequivocal evidence of reliability and relevance for any proposed alternative method.
  • Continued research and validation are necessary to establish a comprehensive battery of in vitro tests for ocular toxicity assessment.